4DMT completed Phase 3 enrollment for 4D-150, a long-acting anti-VEGF treatment for wet age-related macular degeneration, four months ahead of schedule. The trial's primary focus on reducing treatment burden—measuring injection frequency over 52 weeks—addresses a fundamental challenge in managing progressive vision loss and maintaining visual function across the lifespan.
Key Points
- Phase 3 enrollment completed four months early with over 500 patients
- Primary endpoint: non-inferiority in visual acuity; secondary focuses on injection burden reduction
- Long-acting AAV vector delivery designed for multi-year sustained anti-VEGF therapy
Longevity Analysis
Age-related macular degeneration represents one of the leading causes of vision loss in aging populations, directly impairing quality of life, autonomy, and cognitive engagement. Long-acting biologics that reduce treatment frequency lower the cumulative physiological stress of repeated intravitreal injections while maintaining consistent drug delivery—effectively removing a source of procedural burden that can compromise adherence and systemic stability. The rapid enrollment suggests strong clinical demand for therapies that preserve visual capacity without the metabolic cost of frequent intervention cycles.
Original published by Longevity.Technology.